Sudarshan Pharma Industries Limited has disclosed its audited standalone and consolidated financial results for the quarter and financial year ended 31st March 2026. The company submitted a formal communication to the Listing Department of BSE Limited on 4th May 2026, confirming the publication of the results in compliance with applicable listing regulations.

Regulatory Filing and Newspaper Publication

The audited financial results were published as newspaper advertisements in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. The advertisements appeared in the following publications:

• Mumbai Lakshdeep
• Financial Express

The filing, referenced under communication number SPIL/CS/SE/2026-2027/09, was addressed to the BSE Limited's Listing Department at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai.

Filing Details

The key administrative details of the regulatory submission are outlined below:

About the Submission

The notice was signed by Nirav Shah, the Company Secretary and Compliance Officer of Sudarshan Pharma Industries Limited. The company's registered head office is located at 301, Aura Biplex, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai – 400092. The submission requests BSE Limited to take the enclosed newspaper advertisement on record as part of the company's ongoing disclosure obligations.

Sudarshan Pharma Industries Ltd has submitted its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The filing, dated April 6, 2026, was made to BSE Limited as part of the company's regulatory obligations.

Regulatory Compliance Certificate

The certificate was issued by KFIN Technologies Limited, which serves as the registrar and share transfer agent for sudarshan pharma industries . The document confirms compliance with SEBI (Depository and Participants) Regulations 2018 for the fourth quarter of fiscal year 2026.

Certificate Details

KFIN Technologies Limited, acting as the registrar to issue and share transfer agent, certified that details of securities dematerialized and rematerialized during Q4FY26 have been furnished to all stock exchanges where the company's shares are listed. The certificates were issued separately to both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).

The certification was signed by Praveen Chaturvedi, Senior Vice President at KFIN Technologies Limited, confirming the company's adherence to regulatory requirements during the specified quarter.

Company Information

Sudarshan Pharma Industries Ltd operates from its head office located at 301, Aura Biplex, Premium Retail, Premises 7, S.V. Road, Borivali (West), Mumbai. The company secretary and compliance officer, Nirav Shah, submitted the filing to ensure regulatory compliance.

Regulatory Significance

This quarterly certificate filing represents a mandatory compliance requirement under SEBI regulations, ensuring transparency in the dematerialization and rematerialization of securities. The submission confirms that the company has maintained proper records and reporting standards as required by India's securities market regulations.